PsychoPharmacology News

By Circle Of Insight ProductionsBusiness Science Social Sciences Medicine Health & Fitness

PsychoPharmacology News episodes

May 26 The Accidental Mind: Serendipity and the Birth of Modern Psychopharmacology part 2
Part two In the mid-20th century, a handful of chance observations transformed psychiatry from an asylum-bound specialty into a medical field powered by effective drugs. This episode explores how chlorpromazine emerged from industrial dyes and surgical experiments, how imipramine and lithium were stumbled upon while chasing unrelated ideas, and how these discoveries reshaped our understanding of mental illness. Join us for a fascinating journey through scientific luck, keen observation, and the drugs that freed millions from institutional walls.1
5 min
May 25 The Accidental Mind: Serendipity and the Birth of Modern Psychopharmacology part 1
In the mid-20th century, a handful of chance observations transformed psychiatry from an asylum-bound specialty into a medical field powered by effective drugs. This episode explores how chlorpromazine emerged from industrial dyes and surgical experiments, how imipramine and lithium were stumbled upon while chasing unrelated ideas, and how these discoveries reshaped our understanding of mental illness. Join us for a fascinating journey through scientific luck, keen observation, and the drugs that freed millions from institutional walls.
4 min
May 21 Curcumin: Turmeric’s Golden Promise for Blood Sugar and Mood – Evidence, Arguments For and Against
Explore the 2026 meta-analysis and supporting studies on curcumin for prediabetes, type 2 diabetes, depression, and anxiety, weighing compelling arguments in favor of its use against important limitations and counterpoints. We break down benefits like improved glycemic control and mood support alongside bioavailability issues, study flaws, safety concerns, and why it’s no miracle cure. This balanced episode includes a layman’s summary, real-world example, and practical guidance for anyone considering turmeric or supplements
7 min
May 20 Dextromethorphan ( think cough syrup) for OCD: A Promising Glutamate-Targeted Augmentation Strategy?
A small 2026 randomized controlled trial found that adding low-dose dextromethorphan (DXM, 15 mg twice daily) to ongoing SSRI treatment significantly reduced Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores in adults with SSRI-resistant OCD, dropping from about 26.6 to 16.3 over 12 weeks versus little change on placebo. Strengths include its double-blind, placebo-controlled design, strong statistical effect size, excellent tolerability with no reported side effects, and alignment with the glutamatergic hypothesis of OCD. Limitations center on the tiny sample size (n=40), single-center location in Iran, lack of secondary outcomes or long-term follow-up, and potential pharmacokinetic variability from SSRI interactions; broader evidence from meta-analyses of other glutamatergic agents supports the approach but calls for larger confirmatory trials.
8 min
May 15 Antidepressants and Suicide Prevention: Lessons from Korea’s 2002 Prescription Restrictions
A recent study examines how South Korea’s 2002 limits on SSRI prescribing by primary care physicians coincided with a striking rise in national suicide rates. This episode reviews the Korean evidence alongside international research on antidepressant access and suicide trends, highlighting methodological strengths and limitations. It concludes with balanced policy implications for mental-health care that weigh risks of both overprescribing and restricted access.
8 min
May 05 Silent Slip: How Medications Are Fueling Falls in Our Elderly
This episode explores the alarming link between common medications and falls among older adults, revealing how psychotropics and polypharmacy contribute to up to three-quarters of incidents in nursing homes. Drawing on key studies, it details high-risk drug classes and their mechanisms while offering practical prevention strategies like medication reviews and lifestyle interventions. Essential listening for families, caregivers, and healthcare professionals seeking to safeguard elderly independence and reduce preventable injuries.
6 min
May 03 The Dangerous Tetrad: Mastering the Fatal Signs of Rigidity and Fever -case study
In the ER, seconds matter when identifying the "Dangerous Tetrad": rigidity, fever, autonomic instability, and altered mentation. This episode breaks down the clinical markers and pathophysiology of these life-threatening syndromes to help clinicians differentiate between NMS and Serotonin Syndrome. A must-listen for healthcare professionals looking to sharpen their diagnostic skills and improve patient outcomes in high-acuity settings.
6 min
April 27 Antidepressant Withdrawal: 50% of Long-Term Users Suffer? Shocking JAMA Study vs Real-World Reality Exposed
Psychiatrists are clashing over antidepressant withdrawal: clinic data shows up to 50% of long-term SSRI/SRI users face severe symptoms, while a major 2025 JAMA Psychiatry meta-analysis claims they’re usually mild and brief. We break down both sides, expose the massive limitations in the studies, and reveal what this means for millions on these drugs.
11 min
April 26 Metabolic Brake or Muscle Catalyst? The Pharmacokinetics of GLP-1 Muscle Loss
While GLP-1 receptor agonists are not inherently "muscle-toxic," the rapid metabolic shift they induce can lead to a catabolic state that consumes lean tissue. In this episode, we dive into the pharmacology of semaglutide and tirzepatide, examining how slowed gastric emptying and blunted appetite signals impact the leucine threshold required for muscle protein synthesis. We explore the "glucose-alanine cycle," the role of myostatin inhibitors in future drug pipelines, and how adjusted protein dosing ($1.2$ to $1.6\text{ g/kg}$) can act as a pharmacological safeguard against sarcopenia.
5 min
April 20 Ibogaine: Miracle Cure or Medical Gamble? The Truth Behind a Controversial Psychedelic
This episode explores ibogaine as a controversial psychedelic treatment for addiction, examining its reported effects on opioid withdrawal, cravings, and psychological insight alongside serious cardiac and neurological risks. It provides a balanced, evidence-based analysis of ibogaine research, including limitations such as lack of randomized trials, selection bias, and short-term outcome data. Ideal for listeners interested in addiction science, mental health innovation, neuroscience, and the risks and promise of emerging psychedelic therapies.
8 min

About PsychoPharmacology News

From the publisher's feed

Psychopharmacology: Drugs, the Brain & Behavior explores what medications actually do to the brain—and what the research really says about their benefits, risks, controversies, and unexpected…